Company intelligence / Profile preview

NCTx

San Jose/Monrovia, California, United States

Ownership: Private
Development stage: Other

Overview

NCTx has demonstrated a breakthrough in biomanufacturing N-trans-caffeoyltyramine (NCT), a rare compound with potential applications in liver and gut health. Achieved lab-scale production with high purity and yield, progressing from concept to gram-scale production in 5 months.

Therapeutic areas: Gastroenterology
Modalities: Small molecules
Industry: Biotech

Partnerships

Seeking partnerships for co-development and licensing

Beyond the preview

Go deeper on NCTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCTx.

Explore the full profile